Nuclear transport modulators and uses thereof
View Patent ↗The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
1. A method for treating a disorder associated with CRM1 activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof:
wherein the disorder is selected from an inflammatory disorder, an autoimmune disorder and a neurodegenerative disorder.
2. The method according to claim 1 , wherein the disorder is multiple sclerosis.
3. The method according to claim 1 , wherein the disorder is lupus.
4. The method according to claim 1 , wherein the disorder is amyotrophic lateral sclerosis.
5. The method according to claim 1 , wherein the disorder is rheumatoid arthritis.
6. A method for treating traumatic brain injury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.